Fibronectin and diabetes mellitus: Factors that influence its plasmatic concentrations and usefulness as a marker of late complications;Fibronectina y diabetes mellitus: Factores que influyen en las concentraciones plasmáticas y utilidad como marcador de complicaciones tardias

Medicina Clinica

Volumn 112, Issue 2, 1999, Pages 45-50

  Simó, Rafael ^a   Segura, Rosa María ^a   García Pascual, Luis ^b   Masmiquel, Lluís ^a   Burgos, Rosa ^a   Hernández, Cristina ^a   Martí, Ramón ^a   Mesa, Jordi ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBRONECTIN;

ADULT; ARTICLE; BLOOD; BODY MASS; COMPARATIVE STUDY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZATION; RISK FACTOR; TIME;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRONECTINS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RANDOM ALLOCATION; RISK FACTORS; TIME FACTORS;

EID: 0033596457     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Mosseson MW, Amrani DL. The structure and biologic activities of plasma fibronectin. Blood 1980; 56: 145-158.
2. Tamkun JW, Hynes RO. Plasma fibronectin is synthetized and secreted by hepatocytes. J Biol Chem 1985; 258: 4.641-4.647.
3. Vincent PA, Saba TM, Lewis E, Cho E. Contribution of hepatic fibronectin synthesis to regulation of plasma fibronectin. Am J Physiol 1989; 26: 1.406-1.416.
4. Jaffe EA, Mosher DF. Synthesis of fibronectin by cultured human endothelial cells. J Exp Med 1978; 147: 1.779-1.791.
5. Yamada KM, Olden K. Fibronectins: adhesive glycoproteins of cell surface and blood. Nature (Lond) 1978; 275: 179-184.
6. Timpl R, Dziadek M, Structure. development and molecular pathology of basement membranes. Int Rev Exp Pathol 1986; 29: 1-112.
7. Oh E, Pierschbacher M, Ruoslathi E. Deposition of plasma fibronectin in tissue. Proc Natl Acad Sci USA 1981; 78: 3.218-3.221.
8. Deno DC, Saba TM, Lewis EP. Kinetics of endogenously labeled plasma fibronectin: incorporation into tissues. Am J Physiol 1983; 245: 564-575.
9. Clark RA, Quinn JH, Winn HJ, Lanigan JM. Dellepella P, Colvin RB. Fibronectin is produced by blood vessels in response to injury. J Exp Med 1982; 156: 646-651.
10. Kerényi T, Voss B, Rauterberg J, Fromme HG, Jellineck H, Hauss WH. Connective tissue proteins on the injured endothelium of the rat aorta. Exp Mol Pathol 1985; 43: 151-161.
11. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994; 59: 612-618.
12. Dixon AJ, Burns J, Dunnill MS, McGee JOD. Distribution of fibronectin normal and diseased human kidneys. J Clin Pathol 1980; 33: 1.021-1.028.
13. Falk RJ, Scheiman JI, Maver SM, Michael AF. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes 1983: 32 (Supl 2): 34-39.
14. Khono T, Sorgente N, Ishibashi T, Goodnight R, Ryan SJ. Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci 1987; 28: 506-514.
15. Stenman S, Von Smitten K, Vaheri A. Fibronectin and atherosclerosis. Acta Med Scand 1980; 642: 165-170.
16. Houdijk WPM, Sixma JJ. Fibronectin in artery subendothelium is important for platelet adhesion. Blood 1985; 65: 598-604.
17. Garcia Frade J, Tolon R, Garcia Avelló A, De la Calle H. Fibronectina plasmática y procesos arteriosc eróticos. Rev Clin Esp 1986 178: 226-228.
18. Kloczko J, Wojtukiewicz M, Bielawiec M, Zuch A. Alterations of haemostasis parameters with special reference to fibrin stabilization, factor XIII and fibronectin in patients with obliterative atherosclerosis. Thromb Res 1988; 5: 373-390.
19. Leutenegger M, Birembault P, Poynard JP, Eschard JP, Ricard Y, Caron Y et al. Distribution of fibronectin in diabetic skin. Pathol Biol 1983: 31: 45-48.
20. Heickendorff L, Rasmussen LM, Thogersen VB, Ledet T. Analysis of connective tissue components in arterial tissue. Scand J Clin Lab Invest 1990: 50 (Supl 202); 155-158.
21. Nerlich A, Schleicher E. Immunchistochemical localization of extracellular matric components in human diabetic glomerular lesions. Am J Pathol 1991; 139: 889-899.
22. Ljubimov AV, Burgeson RE, Butkowski RJ, Couchman JR, Zardi L, Ninomiya Y et al. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem 1996; 44: 1.469-1.479.
23. Roy S, Cagliero E, Lorenzi M. Fibronectin overexpression in retinal microvessels of patients with diabetes. Invest Ophthalmol Vis Sci 1996; 37: 258-266.
24. Simó Canonge R. Fibronectina y diabetes mellitus. Endocrinología 1992; 39: 62-68.
25. World Health Organization Study Group en Dia betes Mellitus. Technical report series 727. Ginebra: WHO. 1985.
26. American Diabetes Association. American Academy of Neurology. Report and recommendations of the San Antonio Conference on diabetic neuropathy. Diabetes Care 1988; 11: 592-597.
27. Kelly JJ Jr. Electrophysiological findings in peripheral neuropathies associated with monoclonal antibodies. Muscle Nerve 1983; 6: 504-509.
28. Jarret RJ, Keen H, Grabauskas V. The WHO multinational study of vascular disease in diabetes. 1: General description. Diabetes Care 1979; 2: 175-186.
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in pasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
30. Naito HK. Reliability of lipid, lipoprotein and apolipoprotein meassurements. Clin Chem 1988; 34: (Supl B): 84-94.
31. Clark RAF. Potential roles of fibronectine in cutaneous wound repair. Arch Dermatol 1988; 124: 201-206.
32. Tarsio JF, Wigress B, Rhode TD, Rupp WM, Buchwald H, Furchl LT. Non-enzimatic glycation of fibronectin and alterations in the molecular association of cell matrix and basement membrane components in diabetes mellitus. Diabetes 1985; 34: 477-484.
33. Cavalot F, Anfossi G, Russo i, Mularoni E, Massuco P, Mattiello L et al. Nonenzymatic glycation of fibronectin impairs adhesive and proliferative properties of human vascular smooth muscle cells. Metabolism 1996; 45: 285-292.
34. Cagliero R, Maiello M, Boeri D, Roy S, Lorenzi M. Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest 1988; 82: 735-738.
35. Roy S, Saa R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes of high glucose: phenomenon with a memory. Proc Natl Acad Sci USA 1990; 87: 404-408.
36. Blumenstock FA, Valeri CR, Saba TM, Cho E, Melaragno A, Gray A et al. Progressive loss of fibronectin-mediated opsonic activity in plasma cryoprecipitate with storage. Role of fibronectin fragmentation. Vox Sang 1988; 54: 129-137.
37. Bowen M, Muller T. Influence of sample preparation on estimates of blood fibronectin concentration. J Clin Pathol 1983; 36; 233-235.
38. Eriksen HO, Clemmensen I, Hansen MS, Ibsen KK. Plasma fibronectin concentration in normal subjects. Scand Clin Lab Invest 1982; 42; 291-295.
39. Dejgaard A, Andersen T, Christoffersen P, Clemmensen J, Gluud C. Plasma fibronectin concentrations in morbidly obese patients. Scand J Clin Lab Invest 1984; 44: 207-210.
40. Cornell RP. Reticuloendothelial hyperphagocytosis occurs in streptozocin-diabetic rats. Diabetes 1982; 31: 110-118.
41. Gluud C, Dejgaard A, Clemmensen I. Plasma fibronectin concentrations in patients with liver disease. Scand J Clin Lab Invest 1983; 43: 533-537.
42. Owens MR, Cimino CD. Synthesis of fibronectin by isolated perfused rat liver. Blood 1982; 59: 1.305-1.309.
43. Dejgaard A, Andersen T, Gluud C. The influence of insulin on the raised plasma fibronectin concentration in human obesity. Acta Med Scand 1986; 200: 269-272.
44. Stenman S, Vaheri A. Distribution of a major tissue protein, fibronectin, in normal human tissue J Exp Med 1978; 147: 1.054-1.064.
45. Falcone DJ, Salisbury BGJ. Fibronectin stimula-tes macrophage uptake of low density lipoprotein-heparin-collagen complexes. Arteriosclerosis 1988; 8: 263-273.
46. Andresen JL, Rasmussen LM, Ledet T. Diabetic macroangiopathy and atherosclerosis. Diabetes 1996; 45 (Supl 3): 91-94.
47. Simó R, Masmiquel L, García-Pascual L, Burgos R. Mateo C. Segura RM et al. Serum concentrations of laminin-P1 as an index of diabetic microangiopathy. Diab Res Clin Prac 1996; 32: 45-53.